Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Henlius Prices Hong Kong IPO at the Bottom of the Range, Raising $410 Million

publication date: Sep 19, 2019

Shanghai Henlius Pharma raised $410 million in its Hong Kong IPO at a market cap of $2.9 billion, the low end of the range. The company is the majority-owned biologics subsidiary of Fosun Pharma. At the top end of the range, Henlius would have raised $477 million in its debut offering. Fosun and Henlius, a US company, formed the China biologics JV in 2010. In February, the company was approved for a China launch of a biosimilar to Roche's Rituxan, a lymphoma treatment. More details....

Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China